Literature DB >> 16681757

Association between CD31 expression and histopathologic features in stage IB squamous cell carcinoma of the cervix.

A L Silva-Filho1, P Traiman, S A Triginelli, F M Reis, M S Pedrosa, D Miranda, E S Abreu, R Macarenco, J R Cunha-Melo.   

Abstract

This study was undertaken to evaluate the association between the expression of CD31 in the tumor and the histopathologic findings in patients with carcinoma of the cervix. This study included prospectively 30 women, aged 46.6 +/- 10.7 years, with stage IB squamous cell carcinoma of the cervix submitted to radical hysterectomy from November 2001 to September 2002. Samples from the tumor were taken and immunohistochemically evaluated by a monoclonal antibody for CD31. Clinicopathologic characteristics such as stage, tumor size, grade of differentiation, lymphatic vascular space invasion (LVSI), parametrial involvement, and status of pelvic lymph nodes were also recorded. The clinical stage (FIGO) was IB1 in 22 patients (73.3%) and IB2 in 8 patients (26.7%). The expression of CD31 was significantly associated with tumor size and the presence of LVSI, but not with grade of differentiation and vaginal or parametrial involvement (P= 0.03, P= 0.032, P= 0.352, P= 0.208, and P= 0.242, respectively). On univariate analysis, the presence of pelvic lymph node metastasis was influenced by LVSI (P= 0.003) and CD31 expression (P= 0.032). However, on multivariate analysis, the presence of LVSI (P= 0.007) was the only independent predictor of pelvic lymph node metastasis. The CD31 expression in tumor is significantly associated with LVSI and tumor size in patients with early-stage squamous cell carcinoma of the cervix.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16681757     DOI: 10.1111/j.1525-1438.2006.00362.x

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  3 in total

Review 1.  Targeting angiogenesis in advanced cervical cancer.

Authors:  Ramez N Eskander; Krishnansu S Tewari
Journal:  Ther Adv Med Oncol       Date:  2014-11       Impact factor: 8.168

Review 2.  Development of bevacizumab in advanced cervical cancer: pharmacodynamic modeling, survival impact and toxicology.

Authors:  Ramez N Eskander; Krishnansu S Tewari
Journal:  Future Oncol       Date:  2015       Impact factor: 3.404

3.  Diagnostic Modalities of Precancerous and Cancerous Cervical Lesions with Special Emphasis on CD31 Angiogenesis Factor as a Marker.

Authors:  Bandana Sharma; Neetu Singh; Neena Gupta; Pavika Lal; Shefali Pande; Shashi Chauhan
Journal:  Patholog Res Int       Date:  2013-09-17
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.